The 2nd meeting of the International Lipid Expert Panel (ILEP) was finished!

The 2nd meeting of the International Lipid Expert Panel (ILEP) was finished!

The 2nd meeting of the International Lipid Expert Panel (ILEP) was finished❗ For me personally it was one of the most important meeting in last many years. Finally I was able to invite and to host in my native Lodz 20 Polish and International hasztag#ILEP Experts from Slovakia, Czechia, Greece, Croatia, Latvia, UK, Israel, and […]

Questionnaire on knowledge about inflammation as a risk factor for cardiovascular diseases, on possible diagnosis, and management in the context of residual cardiovascular risk.

Questionnaire on knowledge about inflammation as a risk factor for cardiovascular diseases, on possible diagnosis, and management in the context of residual cardiovascular risk.

Dear Colleagues and Friends, We kindly invite you to complete a short questionnaire on knowledge about inflammation as a risk factor for cardiovascular diseases, on possible diagnosis, and management in the context of residual cardiovascular risk.https://ptlipid.pl/ankiety/how-important-is-inflammation-as-a-residual-cardiovascular-risk-factor-the-knowledge-perception-and-management/ The results of the questionnaire will help in planning educational activities and preparing a short, very practical Expert Document […]

Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data

Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data

Within the group of the recognized Polish experts, based on the data from the PL-ACS Registry, for the first time in the world we confirmed that the upfront combination lipid-lowering therapy is superior to statin monotherapy for all-cause mortality in patients with ACS. These results suggest that in high-risk patients, such an approach, rather than […]

Association between electronic nicotine delivery systems use and risk of stroke: a meta-analysis of 1,024,401 participants

Association between electronic nicotine delivery systems use and risk of stroke: a meta-analysis of 1,024,401 participants

Within LBPMC Group we also evaluated the relationship between electronic nicotine delivery systems (ENDS) use and the risk of stroke when compared to non-smokers. The results were presented at the ESC Congress in Amsterdam and published simultaneously in the Archives of Medical Science.  https://www.archivesofmedicalscience.com/Association-between-electronic-nicotine-delivery-systems-use-and-risk-of-stroke-a,171473,0,2.html 

New ILEP individual recommendations for patients with statin intolerance!

New ILEP individual recommendations for patients with statin intolerance!

Statins are a widely available, cheap, safe, and extremely effective means to reduce the cardiovascular disease (CVD) risk, and it is therefore a tragedy that these life-saving medicines are under-used. Non-adherence to statin therapy reaches up to 60% after 2 years, and cessation is associated with a significant increase in the risk of CVD events. Much of this […]

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

Abstract Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3–5%). Many […]